| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968591 | Vaccine | 2011 | 5 Pages |
Abstract
SII HibPRO vaccines manufactured in small and industrial scale are equally immunogenic, safe and confer adequate seroprotection to infants of 6-14 weeks of age. Scaling up production process has not affected the safety and immune response in the target population.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Siddhivinayak Hirve, Ashish Bavdekar, Sanjay Juvekar, Dhiraj Agarwal, Prajakt Barde, Somnath Mangrule, Moreshwar Patwardhan, Anand Pandit, Prasad S. Kulkarni,